Kilambi News
Thursday, November 19, 2026

Archive

Every story, newest first.

Thursday, November 12, 2026

Commodities

Nigeria meets OPEC quota for sixth straight month

Nigeria produced an average of 1.51 million barrels a day of crude oil in October, 101 percent of its 1.5 million barrel OPEC quota, meeting the target for a sixth consecutive month, the upstream regulator said.

Commodities

India Gulf crude imports overtake Russian supplies in November

India has imported about 2.1 million barrels a day of crude from the Persian Gulf so far in November against 1.8 million from Russia, the first time Gulf volumes have led since the Iran war began, according to Kpler data reported by Bloomberg.

Commodities

Gold falls below 4000 dollars as December hike priced

Spot gold fell for a third straight day on Thursday, trading near 3868 dollars an ounce by late morning in New York after losing more than 1 percent on Wednesday, as traders fully priced a December Federal Reserve rate hike.

Commodities

Germany approves state gas reserve after missing storage target

Germany's government confirmed on Wednesday it will build a 24 terawatt hour state crisis gas reserve funded by user surcharges, after national storage ended October at 62 percent against a 70 percent target.

Life Sciences

VectorY adds 83.5 million dollars to fund ALS gene therapy trial

Amsterdam-based VectorY added 74.5 million euros, or 83.5 million dollars, to its Series A, including a 30 million euro European Investment Bank convertible loan, to carry its ALS gene therapy through its Phase 1/2 readout.

Life Sciences

United States loses measles elimination status held since 2000

A Pan American Health Organization expert panel has determined that the United States has lost the measles elimination status it held since 2000, after the same strain circulated without a break for more than 12 months, with 5,412 confirmed cases reported in 2026.

Life Sciences

Neurosterix closes 105 million dollar Series B for schizophrenia drug

Neurosterix, the Addex spin-out, closed a 105 million dollar Series B to fund Phase 2 development of NTX-253, its oral M4 modulator for schizophrenia.

Life Sciences

Life sciences also notable: Omniose deal, Compass filing, FDA staffing

AstraZeneca bought vaccine partner Omniose for undisclosed terms, Compass Pathways completed its psilocybin filing, and FDA review divisions are running 1,343 staff below their 2024 level.

Life Sciences

Caplyta wins second Phase 3 trial in bipolar mania

Johnson & Johnson said Caplyta cut mania scores 3.7 points more than placebo in Study 452, its second pivotal Phase 3 win in bipolar I mania.

Life Sciences

Beeline afimetoran posts detailed Phase 2 lupus results

Beeline's oral afimetoran produced SRI-4 response rates of 64 to 68 percent against 34.4 percent on placebo at week 48 in detailed Phase 2 lupus data presented November 11.